Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
Catalog No. | Product Name | Size | List Price (US$) | Quantity |
---|
Price/availability/specifications subject to change without notice. Unless otherwise indicated, our catalog and customized products are for research use only and not intended for human or animal diagnostic or therapeutic use.
Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
Background Information:
CB-1158 (INCB01158) is an orally bioavailable, potent (IC50 = 98 nM), and selective (minimal off-target activity at 50000 nM) inhibitor of human arginase I, an immune-mediated anti-tumor agent. L-arginine is a critical metabolite for T-cell receptor signaling and subsequent T-cell proliferation, and depletion of arginine arrests T-cell growth. In the tumor microenvironment, infiltrating myeloid-derived suppressor cells (MDSCs), macrophages, and neutrophils produce arginase, which depletes local arginine concentrations and dampens T cell-mediated immune surveillance. Pharmacological inhibition of arginase is expected to restore arginine levels and allow T-cells to proliferate, thereby leading to an immune-mediated anti-tumor response. In culture, human granulocytes release arginase and deplete media arginine to levels that inhibit T-cell proliferation. In a co-culture system of human granulocytes and T-cells, CB-1158 potently blocks granulocyte-derived arginase activity, maintains extracellular arginine levels, and restores proliferation of T-cells (ref. 1). CB-1158 has single agent efficacy in mouse tumor models and synergistically enhances the antitumor efficacy of checkpoint inhibitors (ref. 2).
Reference:
1. M Works, et al, Abstract 552: Immuno-oncology agent CB-1158 is a potent and selective arginase inhibitor and causes an immune-mediated anti-tumor response, AACR; Cancer Res 2016; 76(14 Suppl): Abstract No 552.
2. K. P. Papadopoulos, et al, A first-in-Human Phase 1 Study of CB-1158, a Small Molecule Inhibitor of Arginase, as Monotherapy and in Combination with an Anti-PD-1 Checkpoint Inhibitor in Patients (pts) with Solid Tumors, J Clin Oncol 35, 2017 (suppl; abstr 3005).
3. Validated by a quantitative elemental analysis.
APIM050027: CB-1158 (INCB01158)
CAS No.: 2095732-06-0.
Molecular Formula: C11H22BN3O5.
Molecular Weight: 287.1 (or refer to Certificate of Analysis, batch-spedific).
Purity: 99% by achiral and chiral HPLCs ( detected at 210 nm wavelength).
QC: Achiral and Chiral HPLCs, MS, NMR and Quantitative Elemental Analysis.
Solubility: >100mM in Water
Storage: Refer to Certificate of Analysis.
Copyright © 2009-2022 sydlabs.com. All rights reserved.
Use of this website means that you have read, understood, and accepted the Syd Labs Privacy Policy and Terms & Conditions.